These results are consistent with previous analysis of CD19 expression in patients with R/R DLBCL after treatment with loncastuximab tesirine and subsequent CD19-directed CAR T-cell therapy.39 Fourteen patients received a median of 2 cycles (range, 1-7) of loncastuximab tesirine: 8 patients had refractory disease, 5 patients had a PR, and 1 patient had a CR. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.